PMID- 16815346
OWN - NLM
STAT- MEDLINE
DCOM- 20060829
LR  - 20151119
IS  - 0037-1963 (Print)
IS  - 0037-1963 (Linking)
VI  - 43
IP  - 3 Suppl 5
DP  - 2006 Jul
TI  - Treatment of immune thrombocytopenic purpura in adults.
PG  - S3-10; discussion S18-9
AB  - Idiopathic thrombocytopenic purpura (ITP) is a hematologic disorder characterized 
      by the destruction of antibody-coated platelets in the reticuloendothelial 
      system. Whereas 70% to 80% of children experience the acute form of the disease 
      and recover within a few weeks or months after diagnosis, most adults have 
      persistent disease and will require therapy. Principles of management are largely 
      predicated on the extent of thrombocytopenia and symptoms of disease. Minimizing 
      the toxicity associated with treatment while achieving hemostatic platelet counts 
      are essential goals of treatment. Although there are numerous therapeutic 
      options, neither consensus among experts nor clear algorithms to treat this 
      complex disease exist. This article will review appropriate treatment options 
      available for adult patients with ITP prior to splenectomy, at splenectomy, and 
      following splenectomy. In addition to conventional agents such as corticosteroids 
      and intravenous immune globulin (IVIg), the role of newer therapies with diverse 
      mechanisms of action, such as rituximab, anti-D, and thrombopoietin (TPO)-like 
      agents, will be highlighted. When used as either monotherapy or in combination 
      with conventional therapeutics, these treatments may offer a more tolerable side 
      effect profile and improved clinical benefit compared to existing drugs.
FAU - Bussel, James
AU  - Bussel J
AD  - Department of Pediatrics, Division of Hematology and Oncology, and Department of 
      Pediatrics in Medicine and in Obstetrics and Gynecology, Weill Medical College of 
      Cornell University, New York, NY 10021, USA. jbussel@med.cornell.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Semin Hematol
JT  - Seminars in hematology
JID - 0404514
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Murine-Derived)
RN  - 0 (Rho(D) Immune Globulin)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 9014-42-0 (Thrombopoietin)
SB  - IM
MH  - Adult
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Murine-Derived
MH  - Humans
MH  - Purpura, Thrombocytopenic, Idiopathic/diagnosis/*drug therapy/surgery
MH  - Rho(D) Immune Globulin/therapeutic use
MH  - Rituximab
MH  - Splenectomy
MH  - Thrombopoietin/therapeutic use
MH  - Treatment Outcome
RF  - 56
EDAT- 2006/07/04 09:00
MHDA- 2006/08/30 09:00
CRDT- 2006/07/04 09:00
PHST- 2006/07/04 09:00 [pubmed]
PHST- 2006/08/30 09:00 [medline]
PHST- 2006/07/04 09:00 [entrez]
AID - S0037-1963(06)00091-6 [pii]
AID - 10.1053/j.seminhematol.2006.04.009 [doi]
PST - ppublish
SO  - Semin Hematol. 2006 Jul;43(3 Suppl 5):S3-10; discussion S18-9. doi: 
      10.1053/j.seminhematol.2006.04.009.